Omeros Corporation

NASDAQ:OMER

Biotechnology

Healthcare
$14.55 +4.46%

+$0.43 today

Market cap
$1.08B
Beta
2.53
P/E (TTM)
8.4
EPS (TTM)
$1.20
52W Low $2.95High $17.65

Volume 2.53M

Average 1.55M

OMER Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Omeros CorporationNASDAQ: OMER

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $239K fell 17.3% year over year, behind the -11.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at +0.4% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -17.3% toward the trailing-twelve-month pace of -11.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$239K+1.7% QoQ
Last fiscal yearDec 2025
$964K+1.5% YoY
LTMMar 2026
$914K-11.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.3%——
1 year+1.5%——
3-year CAGR+0.4%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
964K USD
Year-over-year change
+1.5%
4-year CAGR
-8.7%

Depreciation & Amortization vs competitors

How OMER compares with its peers on the latest reported figures

  • OMER's LTM Mar 2026 depreciation & amortization of $914K is the 7th highest of the 11 companies compared; the peer median is $1.84M.
  • Its year-over-year change of -11.7% is the 9th highest of 10, against a peer median of +1.2%.
  • Depreciation & amortization amounts to 9.2% of revenue for OMER, versus a peer median of 4.5%.
OMER Competitors Peer median
Depreciation & Amortization for OMER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHVNBiohaven Ltd.LTM Jun 2026$10.67M +22.9%+92.7%—
XNCRXencor, Inc.LTM Jun 2026$10.17M -10.7%+6.1%9.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026$10M +0.0%+18.6%8.5%
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M -5.1%-15.4%4.5%
ANABAnaptysBio, Inc.LTM Mar 2026$2.43M +1.2%+1.2%1.0%
MREOMereo BioPharma Group plcLTM Mar 2026$1.25M +15.6%+8.7%249.7%
OMEROmeros CorporationLTM Mar 2026$914K -11.7%+0.4%9.2%
NKTRNektar TherapeuticsLTM Jun 2026$537K -72.7%-56.2%1.0%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$314K +2.6%+49.5%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$112K +33.3%-34.1%—
CGENCompugen Ltd.LTM Mar 2026$0 —-0.5%0.0%
Peer median (excluding OMER) $1.84M+1.2%+3.7%4.5%

Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.39M0000
Gross Profit(1.39M)0000
Gross Margin—————
Research & Development118.78M112.72M114.87M119.52M81.3M
Selling, General & Admin53.46M50.67M49.66M49.74M41.5M
Operating Expenses172.23M163.39M164.53M169.26M122.8M
Depreciation & Amortization1.39M952K920K950K964K
EBITDA(170.49M)(158.38M)(143.16M)(157M)(1.83M)
EBITDA Margin—————
Operating Income(173.62M)(163.39M)(164.53M)(169.26M)(122.8M)
Operating Margin—————
Interest Income17.93K4.06M16.34M11.3M5.06M
Interest Expense19.67M22.7M30.84M24.68M0
Other Income / Expenses(17.93M)(18.64M)(10.39M)(13.37M)120M
Income Before Tax(191.55M)(182.03M)(174.92M)(182.63M)(2.8M)
Pre-Tax Margin—————
Income Tax Expense00002.01M
Net Income(111.41M)47.42M(117.81M)(156.82M)(3.35M)
Net Margin—————
EPS (Basic)3.120.46(1.88)(2.70)(0.05)
EPS (Diluted)3.120.46(1.88)(2.70)(0.05)
Weighted Avg Shares62.34M62.74M62.74M58.17M63.51M
Weighted Avg Shares (Diluted)62.34M62.74M62.74M58.17M63.51M

Omeros Corporation

NASDAQ:OMER

Intrinsic Alpha fair value

Locked

Current Price

$14.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.